Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
0.2600
+0.0150 (6.12%)
Dec 19, 2025, 2:51 PM EST - Market open
Akari Therapeutics, Employees
As of December 31, 2024, Akari Therapeutics, had 9 total employees, including 8 full-time and 1 part-time employees. The number of employees decreased by 3 or -25.00% compared to the previous year.
Employees
9
Change (1Y)
-3
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,752,444
Market Cap
9.29M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9 | -3 | -25.00% |
| Dec 31, 2023 | 12 | -3 | -20.00% |
| Dec 31, 2022 | 15 | 6 | 66.67% |
| Dec 31, 2021 | 9 | 0 | - |
| Dec 31, 2020 | 9 | -1 | -10.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AKTX News
- 1 day ago - Akari Therapeutics Releases Virtual Investor “What This Means” Segment - GlobeNewsWire
- 3 days ago - Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market - GlobeNewsWire
- 10 days ago - Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer - GlobeNewsWire
- 15 days ago - Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment - GlobeNewsWire
- 24 days ago - Akari Therapeutics Announces Release of the Next CEO Corner Segment - GlobeNewsWire
- 4 weeks ago - Akari Therapeutics, Plc (AKTX) Shareholder/Analyst Call Transcript - Seeking Alpha
- 4 weeks ago - Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer - GlobeNewsWire
- 5 weeks ago - Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors - GlobeNewsWire